<abstract xmlns="http://www.w3.org/1999/xhtml"><p> We present the case of a 77 year old patient with a primary breast carcinosarcoma composed mostly of an osteogenic sarcoma of fibroblastic type in which only immunohistochemical analysis disclosed the presence of a minor malignant epithelial component. The malignant mesenchymal component derives from dedifferentiation of myoepithelial cells since myoepithelial markers are positive. Also, like the majority of the other metaplastic carcinomas in the breast, carcinosarcoma is a basal type of tumor that will not respond to endocrine drugs or Her2/neu therapy.</p></abstract>

We present the case of a 77 year old patient with a primary breast carcinosarcoma composed mostly of an osteogenic sarcoma of fibroblastic type in which only immunohistochemical analysis disclosed the presence of a minor malignant epithelial component. The malignant mesenchymal component derives from dedifferentiation of myoepithelial cells since myoepithelial markers are positive. Also, like the majority of the other metaplastic carcinomas in the breast, carcinosarcoma is a basal type of tumor that will not respond to endocrine drugs or Her2/neu therapy.

Carcinosarcoma of the breast with massive osseous malignant component: a basal-like entity with myoepithelial differentiation

Department of Pathology, University of Medicine and Pharmacy Târgu Mureş,Str. Gh. Marinescu nr. 50, România

Department of Pathology, University of Medicine and Pharmacy Târgu Mureş, România

Department of Pathology, Clinical Obstetrics and Gynecological Hospital Oradea, România

Revista Romana de Medicina de Laborator

We present the case of a 77 year old patient with a primary breast carcinosarcoma composed mostly of an osteogenic sarcoma of fibroblastic type in which only...

Carcinosarcoma of the breast with massive osseous malignant component: a basal-like entity with myoepithelial differentiation

Published Online: Aug 08, 2013

Page range: 67 - 73

DOI: https://doi.org/10.2478/rrlm-2013-0019

This content is open access.